Trastuzumab,Tucatinib
Seagen,Roche
[]
 approval alert just in time for #ascogi23 tucatinib in combination with trastuzumab is approved for ras wild-type, #her2 positive metastatic #colorectalcancer #crcsm a tki + monoclonal antibody 
Oncologist | Associate Prof | Executive Director-Research, MD Anderson Cancer Network | Medical Director, Clinical Center for Targeted Therapy. Tweets = my own.